Skip to content

Viatris VTRS Current Debt

Current Debt at other companies

Pfizer logo
PfizerPFE
$3.86B+3.0%
McKesson logo
McKessonMCK
$1.13B-53.3%
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
$19.3M+72.4%
AMP
Amphastar PharmaceuticalsAMPH
$1.67M+646%
Aquestive Therapeutics, Inc. logo
Aquestive Therapeutics, Inc.AQST
$14.54M+52.4%
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
$6.2M-80.5%

Other financials

Income statement

See full
Revenue$3.5B+8.1%
Gross profit$1.2B-0.3%
Operating income-$79.7M+97.2%
Net income$176.4M+106%
EPS (diluted)$0.15+106%

Balance sheet

See full
Cash & equivalents$1.8B+139%
Total debt$14.6B+1.0%
Total equity$14.7B-6.3%
Total assets$36.8B-4.3%

Cash flow

See full
Operating cash flow$388.3M-27.5%
CapEx$39.9M-6.3%
Free cash flow$348.4M-29.3%

Valuation

See full
Market cap$20.8B+92.8%
Enterprise value$33.61B+34.5%
P/S1.4×+0.7×

Profitability

See full
Gross margin34.4%-2.5pp
Operating margin1%
Net margin-2%-1.0pp
FCF margin12.3%-1.0pp

Returns & leverage

See full
Return on equity-2%-0.9pp
Debt / equity+0.1×
Current ratio1.6×-0.1×

Where this comes from

Reported directly by Viatris in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtCurrent.

The official record: Viatris’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Viatris's current debt.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Viatris's current debt?
Viatris (VTRS) reported current debt of $1.93B in Q1 2026.
How has Viatris's current debt changed year-over-year?
Viatris's current debt increased by 22618.8% year-over-year, from $8.5M to $1.93B.
What is the long-term trend for Viatris's current debt?
Over 5 years (2020 to 2025), Viatris's current debt has grown at a 11.9% compound annual growth rate (CAGR), from $1.1B to $1.93B.
What does current debt mean?
The portion of long-term debt maturing within the next 12 months, requiring refinancing or repayment from operating cash flows.